TRIL.TO实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 08:00):

Stats
今日成交量	60 423.00
平均成交量	127 472
市值	0.00
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-34.06
ATR14	$0 (0.00%)

TRILLIUM THERAPEUTICS INC 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

TRILLIUM THERAPEUTICS INC 财务报表

Annual	2020
营收:	$148 000
毛利润:	$0.00 (0.00 %)
EPS:	$-0.700

FY	2020
营收:	$148 000
毛利润:	$0.00 (0.00 %)
EPS:	$-0.700

FY	2019
营收:	$124 000
毛利润:	$0.00 (0.00 %)
EPS:	$-1.650

FY	2018
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.25

Financial Reports:

No articles found.

TRILLIUM THERAPEUTICS INC

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.